9ęඈඋ1࣏ۘऺ: Chinese Journal of Tissue Engineering Research www.CRTER.org

වẴ ཐ༘௤ϣĭƚňϬǎẔ¬ȭ͢“ϣՈƽˑ
NJ ˷ z š(ZhǠ¢î͸ÎŦNǠã͸͸½KZhď 100084) DOI:10.3969/j.issn.2095-4344.0266 ORCID: 0000-0002-9653-5741(NJ˷)

তȷợⓉᪿ ũƮK˿K1994 ˝ÛK ཐ༘௤^Ẕ¬Ո͟ி Ųà͟ƜďNK˩ȂKZ Ẕ¬ hǠ¢î͸ÝŸœþKƶ ϙÎāʘǠΌKΏǰ
˗ ʘǠΌ́Ƨ˼·ˏŐõΡ ƅŁƽˑ ཐ൨මିƧ3ዩͧź ᫇ ᅆ ࿆ ཮ ඈ උ Ո £ ~/

Ρ3͢ÂඊྡྷüƄǎ ƽˑ ňϬ ࿁3ཡ࿓Ï᫦3൦ඊ ཐ༘௤(myonectin) ȁ·ȔŀYƚKLþK ɬ௤cAMP3⍝ࡿƄ3 ྡྷϣ“Ո⎅Ï᫦ Ȥ-ęKZhǠ¢î͸Î ྴˏ௤ęû਍$ ŦNǠã͸͸½KZhď ƅŁƽˑ 100084

Ẕ¬ Ě ିǻ:R318 A:ۅDzʃ᪊ ɘ
4ěY2018-01-25 L₎5

-ཐ༘௤(Myonectin)njࢴᜩĿ C1q/ྃӨūȏüƄּ͟ᖏՁ 15( complement C1q/tumor necrosis factor related protein 15 CTRP 15) «ɜɰཐ ͠ՈP࢑,ƧϣĭϏɳĭᯬ & CTRP ᖏՁǪKՈৰ 15 Ĺt

ɜ4

͠Ո5ś᫇ᅆ؄͢ÂՈẠ঳„nj ẝ‡ཐļɳ ͠ʐͱ ͠3= ཐཌྷüƄ(Myokines)ɜɰཐ࿁̻ÑႮ ͠üƄࢴ&8ཐཌྷüƄ9(Myokines)4ƷØ]±ňϬzɜɰཐႮᵯச3࿆཮ʐᖏՁᯬÏ᫦ ẜĩƟɜɰཐ^

ཡ࿓3࿆཮3ȏ࿓ǎ̓࿕7Ⓒẟᜐȭ᪡(crosstalk)ՈǍū ᫇ᅆϘĿÏ᫦źΡ4

ʼᡅ ͠ՈP࢑,ƧϣĭϏɳĭᯬ & CTRP ëཐ༘௤njࢴᜩĿ C1q /ྃӨūȏüƄּ͟ᖏՁ 15 «ɜɰཐྐ

ᖏՁǪKՈৰ 15 Ĺtɜ4ཐ༘௤ńɜɰཐĽŎɳᜬẂ ǛƶĿཐ൨මିƧ3ዩͧǝâʐ͢Âɬ௤3ඊྡྷ üƄ਍Ոƽˑ4

ՈȆᩬཐ༘௤^Ẕ¬Ո͟ி &ήɳ҂҉Ո͏ћȴƇƉǒ4ֲ 5ͩàϬᩥਜ਼ƶ̼௦ęƛ͔ϔǒßǎ PubMed ϔǒß 1999 Ⴗ 2017 À 18 ÀⒸՈDz ̼௦

᪑&8ཐཌྷüƄ ཐ༘௤9ᆵ̼௦᪑&8myonkine myonectin erythroferrone94Ɖǒ൷͑Ƕ┨ʃ βọō 32 ઋDzẟᜐƞ൷ʇ඗4

඗Ș^඗᩾ཐ༘௤dzỞẋͱ ͠z= ͠ՈՈƮś͑ᜄ ňϬz࿆཮ඈඋʐཡ࿓ dž^࿆཮ඈඋʐཡ࿓࿆ ᯬÏ᫦᫇ᅆ ཐ༘௤dzÑƯẟ࿆཮‼ʨ͑ňϬᖏՁȖüՈᜬẂ Ưẟ࿆཮‼Ոʨǚ ┑ĺᜄ±Ⴎϵ࿆཮‼Ո

ˈ¿ dž^ཀྵྚʐྴˏ௤ęûՈǕϣ ÂÆ^ɜɰཐ࿁ₓÏ᫦ƅ༘͟ dž^൦ඊྡྷϣtẋ࣏⎅Ï᫦Ո᫇ᅆ üǸཐ༘௤^Ï᫦ɳ҂҉ƅ௫ǺՈ༘ி4

͟⏲᪑ ཐཌྷüƄmyonectinẔ¬ඈඋȀņ

'L᪑ Ẕ¬Ŀƚཐ ɜɰඈඋ1࣏

Ȗₕᰈ­ ęǪႮϢ࢕ƚȖₕ(31500964)◑ᆵνྲྀȖₕĆ(151095)ęǪĿྲྀʇɴ͔ʥɑᵯ᫂L(2015B046)

(ě˜Ŀྲྀ̓ƚႮ'࢕ۘ᫂L(2016YB047 2017YB028

Biological role of myonectin and its correlation with exercise

Li Lin, Master candidate, Li Lin, Yu Liang (Sport Science College, Beijing Sport University, Beijing 100084, China) Sport Science College, Beijing Sport University, Abstract Beijing 100084, China BACKGROUND: Myonectin (C1q tumor necrosis factor-α-related protein isoform 15) is a novel bioactivator Corresponding author: secreted by skeletal muscle and is the 15th member of CTRP family. Myonectin is specially expressed in skeletal Yu Liang, PhD, Associate muscle and its expression is affected by the type of skeletal muscle fiber, nutritional conditions, other hormones, professor, Sport Science and cytokines. College, Beijing Sport OBJECTIVE: To explore the relationship between myonectin and exercise so as to provide the basis for the University, Beijing 100084, treatment of chronic diseases. China

4 5 6 8 তේǻ:2095-4344(2018)28-04568-06 Li L, Yu L. Biological role of myonectin and its correlation with exercise. Zhongguo Zuzhi Gongcheng Yanjiu. 2018;22(28):4568-4573. DOI:10.3969/j.issn.2095-4344.0266

METHODS: A computer-based search of CNKI and PubMed databases was performed for relevant articles published from 1999 to 2017 using the keywords of “myokine, myonectin, erythroferrone” in Chinese and English, respectively. Finally 32 eligible articles were included in result analysis in accordance with the inclusion and exclusion criteria. RESULTS AND CONCLUSION: Myonectin is released into bloodstream through endocrine or paracrine and works on adipose tissue and liver, involved in adipose tissue and liver lipid metabolism regulation. Nevertheless, myonectin can increase the expression of fatty acid uptake protein gene, promote the uptake of fatty acids and reduce the level of free fatty acids in serum. Notably, myonectin participates in obesity and insulin resistance and correlates with skeletal muscle energy metabolism. It is also involved in erythropoiesis during the regulation of iron metabolism, and therefore, myonectin is closely related to metabolic diseases. Subject headings: Sports Medicine; Muscle, Skeletal; Tissue Engineering Funding: the National Natural Science Foundation of China, No. 31500964; the Fok Ying Tung Education Foundation, No. 151095; the Nationwide Body-Building Project of General Administration of Sport of China, No. 2015B046; the Self-Dependent Research Project of Beijing Sport University, No. 2016YB047 and 2017YB028

0 šᣄ Introduction ᯬₓ᪈ĜȐ˾ʼn/Ǚĝ32͙ɻˬƏK5͙ƸǑƤ ƃǢðõĝY`KɚΛNśÒĝΝDϡƷÛƤ)̼K ʘǠΌĝˍǫɯɷˏK9͙ƸǑƤΌe9ǰK4͙ƸǑƤ Oωǰ
ȷ)˼4ƻǠ¢ƄƏġí͵Ƥ·ǠˏƘÄn̐ erythroferroneĝɷˏK14͙ƸǑƤmyonectinĝɷˏġV ˳ĝͬ̑E9ÆĕƁǟ̧KƯǟ̧ĝȅðϡ4ƃǢ̷ͻʭ ΝD(CVD)=2̀ǂ˥D=Ŋ˝Ȥ͇̓ΝDġKʷȀ͇ÎŦ 2඗ȘResults  ĆǕƍŃ̜ȴ͇Dĝu̚ȼ§ĕƅV 2.1 MyonectinŘ^ MyonectinĆ̵Ʒ˫ĝΌe9ǰKĆ ʘǠΌŰ\RɡĆÎŦ̚KΦʪKƃǢƋÎŦǕƍȴ CTRPνȂĝij15ɲf´KΟCTRP15VCTRPνȂĆȁˎ ͇DĝʩƿKNɜƯRõĖʘǠΌÝÎŦõ̮ĉKƏĝȔ øhūƃŵĝcDNAͥƩ΀ʁ̔IJΛNś2êͥƩ/ζ hKĉ"ƉȆ͸Ʒ˫ʘǠΌæǫɯƗƕˍF9ǰ˼ͻ͇ŤK (expressed sequence tagsKESTs)˼Ά9ȆļœÿƖĜĖ Ń̜ʦƉ̥ǫɯǒüŐõʘǠΌǂ=ūõ̮KͿˍǫɯ ĝūƃŵ(adiponectin)ȅ·ĝɒſLėĝĉ"νȂKȶ ǒüÚɁã=ūǓ=ˇġΦʪͿȆŮõ̮ͿɷˏKĆJĕ νȂf´ųžuūƃŵ˵ţĝʖĆ̼ȆŮKEϟG˛4 ÎŦĉKĝƗϙ·ƅKu͸ŀ ŃśʦƉȌcɡ Όe9 ɩ^ȅĝBʊ—YNʜƂĝ̸˴Ť=ƃĝæ)=°B ǰ[1]K@Ϧĝ Όe9ǰGģ"ˍFJŵ6=ΌeÛA ʊ—˼\Ǡĉ"C1qȅ·ĝCʜƂǑBʊ—Kn ƅŵ(myostatin)=fˠɣˍFÛA9ǰ21(fibroblast growth ́ĝ\Ǡ C1q ϊBʊ—ĝfǠBʊƖǏ͂ŝ9ǰ factor 21KFGF-21)=̦ɩŵ(Irisin)ġVôκBˌ˩ýK Ό ( tumor necrosis factorKTNF)ǜ@śţK9Ư ȶνȂʑ e9ǰĝǫɯěΌeĔƒͿſƘΆƐġͻŦĝÚKEϟ ʐ ɡ \ Ǡ C1q / Ɩ Ǐ ͂ ŝ 9 ǰ ˵ ʩ ĉ " (C1q /tumor Ń̜9ǰ^Wˏ ·ǠˏƘ͛ ¦êɫΓƘΦʪKƯϟ necrosis factor-related proteinKCTRP)[3]V ͆æÔYÎŦƋ̷ͻʭ=õ̮˼̷ŨÒġĝȷ§̚ˌK MyonectinnɲNAŒǠ2q37.3°ĝΆ9%ȢK.A Ƌȴ͇ΝDĝƍƟǜɺƤŨȒœ[2]VɻģŻÝJ½Όƃŵ 9 883 bpKn8ɩȻ˩ǰ˼7ɩˍ˛ǰȆfK%Ȣ2 911 bp (myonectin)ĝÛʦ͸ȔhΛΓÚ9ŵKEƸǑÎŦƋΓ9 ĝmRNAZ̔IJmyonectinĝΆ9ɲij1˴AŒǠ°K. ÛĝÚKƋƃ̢ĝΡ~ŅşŨȒΆœV A8 057 bpKn9ɩȻ˩ǰ˼8ɩˍ˛ǰȆfK%Ȣ2 835 bp ĝ mRNA V Ŷ h ɷ & F Ύ ĝ ǒ ƽ Ƌ ̔ IJ ʘ Ǡ Ό Ȇ Ů 1 ᰈʐ5ͩ Data and methods myonectinĝĉ"2êY̓!şKƷ˫Ý˵ƋǫǰƉƘ 1.1 »Ϙ—́ 40 00050 000ǫ_ǢƗɩ\^ȅiſǂΆ̼ĝmyonectin ̼௦ϔǒßƏˋΉÌ.ɻļœÿΛPubMed ļœ Ǔ3͇ǰóVŶhȅϊĝǒƽƋ12ƛƽĝ̔IJͻ Ə ÿV myonectinŋͬY̓!şƷ˫Ǔ3͇ǰó“˫Ý45 000Ȑ ̼௦rⒸᇇĐ]18˝(1999˝ƀ2017˝)V w[4]VΓĉ"Gģ5ɩBʊ—Yhǫɯĝ̸˴Ť(signal ̼ ௦ ᪑  G ɻ ϗ Ɣ Å ɡ myokine K myonetin K peptideKSP)Bʊ—=NʜƂBʊ—1(N-terminal domain erythroferroneZƏɻϗƔÅɡ Όe9ǰKΌƃŵV 1KNTD1)=žu6ɩGly-X-YƗȧĝ°Bʊ—=NʜƂB ̼௦DzିƧʼnΡ~°Ʒśɻˬ(ƶϙĆΆœΡ ʊ—2(NTD2)˼\ǠC1q/TNFϊBʊ—KΓƏC1q/TNFϊ ~)K^ʼnǸĵ=MetaǫʭΛͮ0ȒɻV Bʊ—ĆCTRP 15Ʒ͠Ûʦ͸ȔhĝƶϙɷˏBʊ—[4]V ̼௦DzₓʃϗƔĜĖ1 642͙ɻˬKΓƏƏˋΉÌ 2.2 Myonectin Ū ×  [ Ù Seldin ġ [4] Ƌ ̔ IJ .ɻļœÿϗƔĜĖ985͙ƏɻɻˬKÝPubMedļœÿϗ myonectinĝȆŮǫ_Λ2êY̓Ƥ!şKƷ˫myonectin ƔĜĖ657͙GɻɻˬV ƶϙáÝͻ
;̈́ƏKƶϙ2êʘǠΌȆŮƏKΓÉ 1.2  ĥͪϥɊ ΖºƘ2êǣ=ά=̹ͬΌ=̷ã˼ˇ=×=Ơ̝=Ɂ ൷͑ʃβ ɻģƖĵˍ`͛ɡΌƃŵKͿŀΌe ã=ɯΛ͋ˮġKEϟΓÝʘǠΌƏĝ2êƘĆǣ=ά= 9ǰǒɻ˵ʩĝQęZ!ȅDž—Ͳô]ΉƷ2ͿÝ+ɗ ̹ͬΌġȆŮĝ5_KĆ̷Ό=ˇȆŮĝ10_ȐwKšÆ ÖŽ°Ʒ2ĝɻģV ȻĝΓ ȆŮΣ̤ɐumyonectin mRNAĝ2êVÆȻK Ƕ┨ʃβ ƏGɻɻˬƗȧQę˼9ʬ+ƋĶˍ`= myonectinÝ̔IJǫ̼ĝC2C12ΌʭˍFƏ2ê˩ƷÞɒK 9ŵ=ʲĝ^ȅĝƗȧQęZ!ɻˬˍ`Όƃŵ^˵ʩ ƯÝɫǫ̼ĝfΌˍFƏΓΣ̤^2ê[4]K^Ćnɷ̺ˍF ĝˍ`Z"ͮ0ɻˬV ǫɯKƖKʘǠΌƯǜʘǠΌɷ̺ˍFĆmyonectinǓ3

P.O. Box 10002, Shenyang 110180 www.CRTER.org 4569 NJ˷ zš. ཐ༘௤ϣĭƚňϬǎẔ¬ȭ͢“ϣՈƽˑ[J]. ęඈඋ1࣏ۘऺ 2018 22(28):4568-4573. DOI:10.3969/j.issn.2095-4344.0266

͇2êĝȆŮK9ÆRşmyonectinɡĽ̀ĝ Όe9ǰK FAT/CD36Ά9ˎ2êð[11]KʘǠΌƋūǓžĝŶh˩Ʒù MyonectinˍǫɯͿ̥ǫɯĝǒüČǚnͻKƶϙĆȔh ξKǜýFAT/CD36ÝʘǠΌūǓžÄnƏΟĖʩϧȔhK ūǓȆŮ˼ɁãKϡu͸ŀƷ˫myonectinĆ̛ˍFÛf ƖmyonectinæȁˎLJdz°Ő ūǓžʳĔĝΆ9 ˎiƏŐ;ǵõ̮ĝƗϙ9ǰ(Ϧᜬ1)V ÔYūǓˍFĝūƉÄnKȁˎÇΏFAT/CD36ĝ2êįÔ YūǓžĝÄn[4]KƯ{u͸ŀƷ˫îIJY̭̓ƣΆƐ˗ ᜬ 1 ཐ༘௤ՈϣĭƚňϬǎ᫇ȋü௤ ŐƤmyonectinĝŋͬKƯȅðǜĉ̼ūǓžŋͬĦKţ ̤myonectin^ ÎŦƋͻ ǜĉ̼ūǓžĝŐ;ȔhK ཐ༘௤ՈϣĭƚňϬ ཐ༘௤Ո᫇ȋü௤ Bˌ˵Ȼõ͛ϙY`ĝôκƸ~V (1)Z᫇dž^࿆཮‼ȼΚՈȖü ཐ൨මିƧήཐ൨මᜬẂ̶ ȷཐ൨ම 2.2.2 MyonectinÝɁãƏĝȔh ɡƤţômyonectin º໐Ưẟ࿆཮‼ʨǚẟ͑ඊྡྷ ᜬẂɅ ( 2)ƯẟཡඊྡྷՈ࿆ᯬʨ͑ ዩͧźΡࡅ“ᜬẂλɅ ẟ“ᜬẂʺ¤ ÝɁãƏĝȔhKhRT-PCRΧĴǫʭ̔IJH4IIEɁˍF ཀྵྚrᜬẂλɅ Ʒ˫K΍ƭͿ\òæǫ5DΟH4IIEɁˍF˼̔IJɁãƏDZ (3)õ:ཡ࿓Ⴎˆ leptin ᪵ȰᜬẂʺ¤ Ĉ˵ʩΆ9Atg7˼Atg12ĝ2êùξKƯƗȆmyonectinæ (4)Ưẟ൦ඊྡྷՈϣt3Ưẟ̺ cAMP3⍝ࡿƄ3PI3K ʺ¤3p38 MAPK λ ҋɳᯯᜄՈʮ̩ Ʌ᪵ȰᜬẂʺ¤ ùξCav1˼Fabp1ĝ2êKÔYūǓžÄ$ĝùξKƖ myonectinæȁˎLJdz°Ő ūǓžʳĔĝΆ9Ô YɁˍFĝūƉÄn[4]VdžȻKSeldinġ[12]Ʒ˫myonectin 2.2.1 MyonectinÝūǓȆŮƏĝȔh ͠ƗCTRPνȂ æΏͻˍFDZĈƅ9ǰmTOR(Œ̒ɎŵěǠ)KΏͻ f´ĆnūǓȆŮǫɯEDZǫɯ=̥ǫɯ˼ˍǫɯǒüȔ PI3K/Akt/mTORȗuÎƯƅɁãDZĈVƯDZĈŐ;ˍF hȰ]Ϳ¹¡ΦʪKƖ\cɡ ūǓ9ǰKƙɜæ ʦƉĝ˾f=C˼Ɨ̵ŶhŭϏĝõ̮ͬ̑Ο̋îĝȔ Ő;ūǓȆŮĝɷˏKYƯŐ;.ÎēŵʉɃ͇=ˏƘõ hKƖmyonectinŋͬĝ3@ϡͮÚĖˏƘõ̮ĝͬ ̮Λ̷ͻʭΝD[5-6]KŸjCTRP 3æƅ̔IJDŨ̷͇ã ̑KĄĆΓ·ƅ͆͛ϙY`ĝôκţʌVɡƤΡ~ ĝƗŹ[7]=CTRP 5æȁˎÔYAMPK̸˴¦ĕùξ;njǂ myonectin˼;njǂŭϏĝʩˊK ƗȆmyonectinĉ"ƿ ĝÄ$Kȷ§ǟ̧̔IJĝ;njǂõ̮[8]VMyonectinĆCTRP ÅĖ̔IJƏƷ˫ɐuĦ;njǂĝȔhKƖmyonectin νȂf´ŭKĄ^ȅĝĆƙĆnʘǠΌǫɯEˍǫɯǒ ƶϙūƉõ̮ʩˊɱϝKɬœSeldinġ[4]ĝQęKÝǠȻ üŐ;ǠˍūƉˊȌĝͬ̑KEϟô˫ʘǠΌ˼ΓƘõ̮Ȇ ƗȆmyonectinȁˎùξÝūǓžʳĔƏΟƗϙȔhĝ Ů(ƶϙūǓȆŮ˼Ɂã)ŭϏĝ Ƌ̽[4]V CD36KFATP1ŋͬ=ùόFabp4 mRNA2êKÔY̔IJū ɡƤƸ~myonectinĝȔhKhmyonectinƗȆĉ"Ȕ ǓˍF˼îIJɁˍFƏĝūǓžÄ$(ϦĚ1)VÆȻKƗȆ h̔IJ̢Ʒ˫FFA(sŦūǓžͿǜĉ̼ūǓž)ŋͬ myonectin Ƌ ū Ǔ Ȇ Ů ū C ɐ u U ́ V 9 Æ æ  ȟ ! ĦKƯūǓˍFūCˏſΣ̤ɐuȷ)Kǜýmyonectin myonectinĉ"ͻ AΉLsɒŋͬæùξūǓȆŮ˼ ÝūǓˍFƋūǓžĝÄ$ƏΟĖƤşĝȔh[4K9]Vǜĉ ɁãƏĝūǓžÄ$KEȷ§ūǓõ̮˼ūƉ¡ŨKĄĆ ̼ūǓžĆͻ ĝfǫŭKÝŞ@ē˗KūǓȆŮĝ ·ƅ±^ ›V ūǓŋCČǚǜĉ̼ūǓžYnͻ
K\ʘǠΌ=Ɂãġ ƗƕȻƛȆŮÄ$ŶhKY̓φ̼ɺˏV
!Myonectin Ħ;̈́ǜĉ̼ūǓžŋͬȁˎ2ƕæˏĝ·ƅYƅūǓ Ȇ Ů ū Ǔ ǫ C Ϳ Ô Y ū Ǔ ž Ä $ Y n ˍ F K  Ć h myonectinǫ5¡Ũ3T3-L1ūǓˍF˼°õȰƛūǓȆ ŮKƷ˫myonectinƋ@Ƨ˗ĝūCΛ×°ˮŵzĕĝūC ¸ɐuƅȔh[4]K9Æ̖šƤij1ƕæˏĝ·ƅZƃ̢η ͫƋmyonectinĆȆÔYƤūǓžĝÄ$Y̓ʬ+KhN˼ άƘĝēŵ(50 nmol/L)˼5 mg/Lĝmyonectin¡ŨūǓ ˍF¸ˏîȎſùξūǓžÄ$KƯȅðhēŵ˼ myonectinĉ"ÇΏūǓˍF^ͮĕƁūǓžÄ$ĝY `ùξK9Æȟ!myonectin˼ēŵùόūƉÄ$ƖΏͻ ĝȗuśţ[4]V ÝūǓžÄnˍFƏΟƗϙȔhĝGģūǓžLJÎĉ "CD36=̔ʈĉ"1 ( caveolin-1KCav1)=ūǓžLJÎĉ "(fatty acid transport protein 1KFATP1)=ūǓžB˾ĉ "(fatty acid bindin protein 4KFABP4)ġĉ"KôκƏŶ Ě 1 ཐ༘௤ňϬzཡ࿓ʐ࿆཮ඈඋ߾͛Ě hRT-PCRǫʭ˩ýÝūǓˍFƏƗȆmyonectinæ^ ȅ i ſ ı ° Ő Ń ̜ Ά 9 ĝ 2 ê K Ý ū õ ̮ ˎ i Ə K 2.2.3 Ő;̛ˍFÛfƏĝǵõ̮ 2014˝KKautzġ[13] FAT/CD36ĆʘǠΌƶϙĝūǓžLJÎǠŭKÝϐš Ʒ˫̔IJæͻͿƿÅƠ̂ˍFÛfŵ̢Kʘƅf̛ˍFƏ FAT/CD36Ά9ĝ̔IJƏ[10]KūǓžÄnʌ˩ϠºKƯĊ CTRP15ĝ%ȢΆ9Fam132b2ê°ŐEÚǠˍǵõ

4570 ISSN 2095-4344 CN 21-1581/R CODEN: ZLKHAH Li L, Yu L. Biological role of myonectin and its correlation with exercise. Zhongguo Zuzhi Gongcheng Yanjiu. 2018;22(28):4568-4573. DOI:10.3969/j.issn.2095-4344.0266

̮Kʛ{ʑʐɡerythroferrone(ERFE)KERFEnf̛ˍF ŤðͲôh;njǂ˼ūǓlʱɯKBˌƷ˫Ɩŀ¸˩Ʒù 9ÛK\κţɡ̛ˍFÛfˎiƏŐ;ǵõ̮ĝƗϙ9ǰK ξ ͻ Ə myonectin ĝ ŋ ͬ K ɐ u ˩ Ʒ - 3 Z 4 Ǣ h æJĕKΏ̛͇ˍFÛfΉϏĝǵŐŵƅV 25 mmol/Lĝ;njǂ˼1 µmol/Lĝǵ™žĉǫ5̱ὡIJ ɡƤƸ~ERFEÝŐõͥͻƏĝȔhKɫ6ƛƽ C2C12ˍFKƷ˫myonectin mRNAĝ2ê¸îȎ°Ő[4]K C57BL/6͎͇̔IJqȭƿÅ500 µLͿh200 ƯˍFÛf Ɩ2ʌOωŋͬĝ)̼ͮŰ4ÚmyonectinĝŋͬKǜ ŵ(EPO)¡ŨKƷ˫˩Ʒ°ŐERFEΆ9(Fam132b)ĝ2 ý·Ǡĝͻǂ˼ͻūæŰ4zĕʘǠΌmyonectin mRNA êKEκţJAK2-STAT5̸˴ȁǮJĕƤ̛ˍFÛfŵƋ ĝ2êK9Æȟ!myonectinæ ȁũΓƘĝȆŮOω Fam132b2êĝÔYȔh[13]VuƲ­Ρ~Ʒ˫Kɫͻ
ȑ ǑēKEÔYΓƘȆŮùξOωĝʳĔ˼[9]V ʭ͉ŀƿÅs͇ͫƠ̂ˍFÛfŵěǠΏŦάͿ̵̀A̚ ɰωĦūǓ¦òĝ̔IJ˵ KɰωɒūŤƨĝ̔IJž ̛ˍFÛfŵƅάKæ˩ƷùξERFEĝͻ ŋͬKŃ u0Ħĝmyonectin mRNA˼ͻ ŋͬ[4]K2ʌǟ̧zĕĝ ϡǜýƤ̛ˍFÛfŵƋNERFE2êĝÔYȔh[14]V ˏƘͬ̑ȷ)æˏǟ̧ǑƧƏmyonectinJĕĝÛŨˎi Kautzġ[15]ȁˎɫϟÛ̀̔IJƿÅξKæͻĝ_ǪĎȾ¹K æŐuʩV>Ưu͸ŀƷ˫ɒūŤωĝîIJʘǠΌƏ ïf̔IJͻ̛ĉ"˹ſ=̛ˍF `˼ͬ¸̛ˍFͻ̛ĉ myonectinĝŋͬ˩ƷÞɒ[17]KɯuPetersonġ[18]Ʒ˫ "˛Ƙ˩ƷĦKDΟΨš͇ͥͻĝƷÛKƯΡ~2ʌ LZR(ĜxĝZuckerîIJKĜŵĝěǠɷˏŞ@)˵ K ERFEæȁˎƅǵŐŵĝ9Û=ùξĈˍFČǚFe2+ OZR(ǟ̧ĝZuckerîIJKĜŵĝěǠ\͵͂)žu˩Ǣɯɒ Ėͻ ΛC°͓ƋǵĝʳĔKÎƯÔY̛ˍFĝÛf= ĝmyonectin2êŋͬKƘɜȟ!leptin(Ĝŵ)Ýmyonectinĝ ÔYΨš͇ͥͻĝͣȧ[13]V Ő;ƏΟȔhKEϟRodriguezġ[19]ȋ]ϡƷ˫leptinæȔ Œ̛ˍFÛfŵlERFEŐõǵŐŵ2êĝ̸˴LJĕ· hΌˍFEzĕmyonectinΆ9ĝ2êKĄŃ͆͛ϙY ƅ u ͸ ŀ ŷ “ ʘ ́ Ƨ Ʒ Û ĉ " (bone morphogenetic `ĝôκţôV proteinKBMP)/SMAD̸˴ȁǮǵŐŵ2êuşĝʩˊK 2.3.3 ΓƘˍF9ǰ=ΏŵġƋmyonectin2êĝÚ ɡƤƸǑBMP/SMAD̸˴ȁǮÝ̛ˍFÛfŵJĕĝ ÆȻKSeldinġ[4]ÝˍFŋͬĝΡ~ƏƷ˫ijƵ̸ø̈́ưž ERFE2êùξΛƅǵŐŵ9ÛƏĝȔhVNaiġ[16]̇ ˮσ(cyclic a-denosine monophosphateKcAMP)ΛȹŦǰ matriptase-24æĝ̔IJϟÛ̀̔IJƿÅ̛ˍFÛfŵK ŋ ͬ ĝ Þ ɒ æ  î Ȏ ù ξ ̔ IJ C2C12 Ό ʭ ˍ F Ə Ʒ˫¸æùξ̔IJʘƅErfe 2êKĄƋǵŐŵĝ2êEɫ myonectinΆ9ĝ2êK9ÆæȟƆÎŦȁˎǜɒcAMP 9ÛƅȔhK9Æȟ!matriptase-24æĕƁBMP/SMAD ˼ȹŦǰŋͬÎƯùξƤmyonectin mRNAĝ2êVĄŶ ̸˴ȁǮɒſΏͻæˏȼHƤEPO/ERFEƋǵŐŵĝƅ hˮσžͻ̼ĉ"Ώɍ(AMP activated protein kinase ȔhV4ǢNaiġ[16]ŶhΆ9ϐš̔IJKY`Ƹ~:ş activatorKAMPK)ĝΏŦά5
`Ά4
ςćĄĒ˺ǂ˺σ matriptase-2æˏȁˎȔhěǠ"ɻ EPO/ERFEƋǵ ž(5-amino-Imidazolecarboxamide- ribosideKAICAR)¡ Őŵ2êĝŐõV ŨC2C12ˍFƷ˫KAICAR˼ēŵ¸^ÚΌʭˍFƏ 2.3 MyonectinŪL̽ʚͩ MyonectinĆnʘǠΌǫɯ myonectin mRNAĝ2êKȟ!Ƌmyonectinĝ2êɐuŐ EDZǫɯ=̥ǫɯ˼ˍǫɯǒü9ÛȔhKʲνKŌ ;Ȕh[4]V ƋmyonectinĝŐõ·ƅY̓Ρ~KƷ˫ΓǫɯƘě͠Ɨ9 džȻK͆uΡ~Ʒ˫ēŵįÖϡͮƋmyonectinŋͬ ŵĝÚ(Ϧ21)V 9ÛÚKΡ~ŀƷ˫Ý̱ωĝnǵ™žĉzĕĝēŵ 2.3.1 Όˠɣś̀Ƌmyonectin2êĝÚ Όˠɣś̀ įÖ̔IJĝΌʭˍFƏKͮ“˫myonectinŋͬ0Ħĝ˫ ĆÚmyonectinǫɯƘĝĖϙ9ŵKSeldinġ [4] Ʒ˫ ̈KϡƷ˫AKt(ĉ"ΏɍB)ͻ͇0ĦKϡƷ˫p38uŜǫƪ myonectin mRNAÝȴΌˠɣɡƶȆfĝ ʲˆΌ(˛Ƕ °Ώͻĉ"(p38 MAPK)ΛưūćΌ·
3Ώɍ(PI3K)¸Ő Ȯĝ˴żǠ)Ə2ê˩ƷɒĉΌˠɣɡƶȆfĝĩΌ ;Ƥmyonectin mRNAĝ2êKôκϡ2ʌæȁˎùξ (˛0ºĝ˴żǠ)KĄĆʘǠΌˠɣś̀Ćj˽Őõ PI3KͿĦp38 MAPKùξmyonectin mRNAĝ2êKƯ myonectin mRNAĝ2ê͆^ʌ:V ǵ™žĉͮϠºPI3KEùξp38 MAPK2êKÎƯĦƤ 2.3.2 Oωǰ
Ƌmyonectin2êĝÚ ͠ƗΡ~ŀƷ myonectin mRNAĝ2ê[20]VdžȻKÝC2C12ΌʭˍFK ˫myonectin Ƌ·ǠĝOωǑēmΓʉɃKSeldinġ[4]Ýɫ °ĵƖƕΏɍĝǓ3͇ƅά¡Ũ̢KƷ˫myonectinĝLJ ̔IJ\òɆ¡Ũ̢Ʒ˫ʘǠΌƏmyonectin mRNAĝ dzŋͬǫ5\ÔY˼ƅ[20]KŒʌmyonectin mRNAĝ2 2êěƅKƯÜɫ̔IJŤƨ̢KʘǠΌƏmyonectin êěˍFĝùŲ=ǫ̼=ΨšġƗƕˍFÛʦ͸ˎiĝU mRNAĝ2êʌ˩°ŐKϟ ʲˆƏΓ°Őĝiſʌ˩ɒ ́Vu͸ŀÝȽrzĕĝ̔IJΌeƍ¬͑ȧΡ~ˎiƏƷ ĩΌKŃϡǜýΌˠɣś̀ͮÚmyonectin mRNAĝ ˫KÝūǓ^ΊˎiƏKmyonectinæÔYūǓˍFƋū 2êKϡu͸ŀÝƋîIJY̓\ò¡ŨÜɫŤƨKƷ˫2 ǓžĝʳĔKEϟ݀ĉȽr˾fƘ 0ɒðKmyonectin h̢ ʲˆƏmyonectinĝ2ê°Ő]$_[17]VEϟÝ\ò mRNAĝ2êƘϡͮÞɒ[21]V ĝ̔IJƏƷ˫Á͇̔IJ ͎͇̔IJǠˍ;̈́ĝmyonectin ƖKΌˠɣĝś̀=Ώŵ=ˍF9ǰͿΓƘ9ŵͮ µƗKÜŤ̢Bˌϡ˵ȅKŃϡˏŒʌ͇5ϡĆÚ ƋmyonectinĝΆ92ê9ÛÚKĄĆKîbǫĝΡ~2 myonectin2êŋͬĝɩ9ŵ[4]VɡƤ+5ĆƷŋ̼˾ʦ ʌƶϙĝÚ9ŵĆOωŋͬĝ)̼KOωǑƧ)̼ðƶ ͆ĆūǓùξƤÜŤ̔IJmyonectin mRNA2êŋͬKÜ ϙæˏȁˎAkt/PI3KȁǮ[22]=AMPK2ê[23]=cAMP˼Ca2+

P.O. Box 10002, Shenyang 110180 www.CRTER.org 4571 NJ˷ zš. ཐ༘௤ϣĭƚňϬǎẔ¬ȭ͢“ϣՈƽˑ[J]. ęඈඋ1࣏ۘऺ 2018 22(28):4568-4573. DOI:10.3969/j.issn.2095-4344.0266

˹ſ)̼ġ9ŵŐõmyonectinǫɯ[4]KƯϟSharmaġ[24] ˵‚ȔK͛ϙY`ĝκţVEϟuφÎŦͮÔYūǓž ʬ+ĖKƘ˳ƅĝîIJƏͻ myonectinŋͬ^)KŃϡκ ĝǫCKmyonectinæÔYūǓžÄ$KƯBˌƷ˫uφ ţƤOωŋͬƋmyonectin9Ûµş͇ÚĝŃȟƆKĄ ÎŦĦƤͻ myonectinŋͬKƖɫįΡ~KȶCµĝ ʲνmyonectinĝŐõ·ƅ͆ʕƽ:şKƖ͛ϙ͠ƗΡ~ ʁǝĆuφÎŦÎŦ̢ʘǠΌˍFƏmyonectinǫɯϠ įƸ~˼ţôV ºĆj˽̠ŐūǓžõ̮ĝV 2.4 MyonectinƒÇŪ:ͧ ʘǠΌĝˍǫɯɷˏÝ˳ 2.4.2 Ŧʦôκ ÝY̓ŦʦôκκţÎŦƋmyonectin ƅǟ̧=ēŵįÖ˼˵ʩΝD(Gģ2̀ǂ˥D)ƏΟƶϙȔ ĝÚðKȁ@ IJśhȓôκƋ̈VSeldinġ[4]Ė˝Ŷh h[25]Kn Όe9ǰĆnʘǠΌˍFǫɯKƖΓǫɯ ̔IJC2C12ΌʭˍFY̓ǠȻôκƸ~ˍFˍ̈́r)̼Ƌ ěΌeĔƒͿſƘΆƐġͻŦĝÚKÎŦðʘǠΌĝĔƒ myonectinĝÚKƷ˫ĊùξȹŦǰĝ˹ſðKmyonectin ĥĦĆΡ~ Όe9ǰĝǫɯðƖ͞ÙǾĝƗϙ9ŵV ĝ2êƃŭùξK4ǢȁˎƋ̔IJY̓Ɩɩ̺ΉĝDZ»LJ ÎŦ9ǰĆΌe9ǰĝɩǫŦKΓ/ǙĆnÎŦ ȍ̭`ΆƐƷ˫K̔IJĩΌ= ʲˆΌƏmyonectin mRNA įŐ;KEϟƃ̢ČǚĖ;̈́ͻ
ƏƷ͠¹Ƃ̚KKƯΓ ĝ2ê¸ÞɒKE4ƃǢ;̈́ͻ
Əmyonectinŋͬĝǜ Ƙĝ Όe9ǰ^şěΌeĔƒõƅKæˏ^žu.Î ɒKÜB˾ǠȻôκΌʭƏmyonectin2êùξĝBˌKȟ ˊȌ͇ĝɷˏKƗϙĝĆ Όe9ǰE^şnʘǠΌǓ ! Î Ŧ z ĕ ĝ ˍ F ˍ ȹ Ŧ ǰ ŋ ͬ ĝ Þ ɒ æ ˏ ° Ő 3͇ǫɯKϡænΓƘȆŮǫɯ[26]Vʲν:şĝÎŦ9ǰ myonectinÝʘǠΌƏĝ2êKǜýmyonectinÝÎŦKΏ u5ɩY"ˍFJŵ6=SPARC(Secreted protein acidic rich in ˗K·Ǡ9ÛÛŨljKƏƷ͠ǢƗϙĝȔhV cysteine)=Angptl4=CX3CL1˼CCL2[26]VnʘǠΌÝƃ u͸ŀÝΡ~̭ƣÎŦƋɒūBòzĕĝǟ̧îIJʘ ΉͿAΉΆƐ̢ͮDΟ¹ƂȆŮ9Û^ȅĝBˌKƖæ ǠΌmyonectin2êĝÚƏK ÒîIJɒūîIJɪǫ ɬœ ÎŦ9ǰĝǫɯʖü ΓY`ǫɡΜ͇Ϳȴ͇[27]V ɡƋĶȆ˼ÎŦȆKÎŦȆh10ƛ=26 m/min=60 min MyonectinŭƖ\Ñȓ Όe9ǰĆnÝ̔IJʘ ĝ̭ƣΆƐKƷ˫ÎŦȆƏîIJ ʲˆΌ˼ƈCΌƏ ǠΌƏϗ!ĖΓLJdz9ǰKEȁˎɷ&FΎÝ̔IJʘǠΌ myonectin mRNA ĝ2êƋĶȆʕ˩Ʒ-3K9Æȟ! _C9ʦ˼L6°
Əϗ!Ėmyonectin[4-28]KƯϟƷ˫̔ ÎŦ^ÚŞ@îIJʘǠΌƏmyonectin mRNA2êŋ IJC2C12ˍFĝǫ̼ˎiͮzĕmyonectinĝ2ê[4]KƯÝ ͬ K Ą Ć A Ή ĝ ɒ ū Ť ω ˩ Ʒ ° Ő Ƥ î IJ ʘ Ǡ Ό Ə ΓƘȆŮƏmyonectinžu˩Ǣ0Ħĝ2êVĄĆKʲνÎ myonectin mRNAĝ2êŋͬKƯÎŦæ˩Ʒ˗Őǟ̧ ŦƋmyonectinǫɯΛ;̈́ŋͬĝÚ=ΓƋ¹ƂȆŮĝȔ îIJʘǠΌƏmyonectin mRNAĝ2ê[17]VMyonectinĝŋ h͆^ʌ:KˏȆş,myonectinɡ ÎŦ9ǰϡ͛ϙY ͬěOω9ŵĝÚK͸ŀRɡʘǠΌƏmyonectinĝ2ê `ĝƸǑV9ÆK͠Ɨ͸ŀŌƋmyonectin˼ÎŦŭϏĝ îIJĝͻū˼ͻǂŋͬf˩ƷŞ˵ʩK̭ƣΆƐĦƤ ʩˊKÎNǠ=ÝǠŦʦ=ǠȻˍFġǒɻY̓ƤΡ~V ǟ̧îIJĝͻū˼ͻǂŋͬKEϏ4˗ŐƤʘǠΌƏ 2.4.1 NǠēκ ɡƤκţuφÎŦΆƐƋmyonectinĝ myonectinĝ2êKƯṋƣÎŦæĦͻ ƏFFAĝ U ́ Λ Ƹ ~ myonectin   ē ŵ į Ö ˼ ˴ ż Ǡ ŋͬKȟ!myonectinæˏ^ ÎŦƋͻ FFAĝŐ;Ȕ DNA(mtDNA)ɱſŭϏĝʩˊKLimġ[29]Ƌ14ʐ23ƇȐw h [17] V Peterson ġ [18] ϡ Ć B ˾ Ƥ ɒ ū ¦ ò ˼ Î Ŧ Ƌ ˼60ƇȐwĝÒ˿͇ôè10ƛĝuφÎŦΆƐα̻Kα myonectin2êĝÚKŶhE͇è,Ȕ)ΧĴ bǫî

̻Bķ̢ƋěēŀY̓ͻ=!şVO2 max=RT-PCRΧĴ IJĝleptiněǠΆ9͵͂ÎƯĕƁîIJǟ̧(OZR)KƯdž ! ş mtDNA E hɿ Ƨʖ ̀ͯ ʑƽ (homeostasis model bǫîIJleptiněǠɷˏƕ˲KîIJ0Ĝx(LZR)KôκƏ assessmentKHOMA)ͯφēŵįÖ(HOMA-IR)KƷ˫ Ʒ˫myonectinΆ92êÝǟ̧îIJʖ̀ƏùξK ƖȆî

ͻ myonectinŋͬĝ)̼ƖȆ˝ƽȆVO2 max=mtDNA IJɪǫɡƋĶȆ˼ÎŦȆKÎŦȆîIJY̓9ƛĝuφΆ ɱſ˼HOMA-IRŋͬĝ)̼u˩Ǣ˵ʩ͇KÎŦÎŦ˩Ʒ ƐKƷ˫ÎŦ¸æϠºǟ̧˼ĜxĝZuckerîIJʘǠΌ

Ħͻ myonectinĉ"ŋͬKȅðVO2 maxǜɒϟŊ˝Ȇ Əmyonectinĝ2êKĄĆÎŦðmyonectin ĝĉ"˛Ƙ˩ 0˝Ȇ˿͇ùξĜƗKʘǠΌƏĝmtDNAɱſùξK˝ ƷÞɒKŃƕɁƓĝ2˫ɯøôκ:RKuφÎŦƋ ˿͇ùξƤ6.6%KŊ˝Ȇ˿͇ùξƤ17.2%KƯϟ myonectinĝÚáÝŚ0K9Æ͆͛ϙY`ĝôκY̓ HOMA-IRŋͬ(ēŵįÖŋͬ)ĦKuφΆƐ̢IR\ȷ Ρ~KEƸǑΓÚĝ·ƅV §[29]K9Æmyonectin˼ēŵįÖ˼mtDNAɱſŭϏá ÝşĝʩˊK͛ϙY`ĝôκY̓Ƹ~V 3

Ƀ඗^ʉƗ

Conclusion and prospects
˴żǠɷˏİmtDNAɱſKmtDNAĝļƘ˼ƉƘ MyonectinĆʘǠΌǫɯĝƕÛʦͻ͇9ǰKæȁˎ ĝ)̼;njǂŐ;ěƍuʩ[30-31]VŐõ˴żǠɷˏĝ ˍǫɯĝ́üȔhȻƛūǓȆŮ˼ɁãK ūǓȆ ɩƗϙĝĉ"ĆAMPKKuφÎŦ̢AMPK\ΏͻKƃŭ Ů˼ɁãūƉõ̮Ő;KæȁˎÔYūǓžĝÄ$K PGC-1α\AMPKŰ4ưž̼Thr / SerƯΏͻKÔY˴żǠ ùξūƉõ̮KmyonectinȔhĝ·ƅΡ~æÝūǓõ ĝÛʦ˾fKÎƯǜɒ˴żǠĝ̣ʳɷˏKȷ§IR[32]KƯ ̮ʀȉĕƁĝΝDƍƟƏžuŷĕ),KϡÝʲνΡ~ u͸ŀƷ˫AMPKα2ϐšĝ̔IJƏmyonectin2êŋͬ KļϠǟƏÇȱ“̵ĝřǮVȋ̵Ρ~Ʒ˫ƙ ̛ˍ ĦKƖAMPKæ°Őmyonectinĝ2ê[23]Kѐlimġ[29] F Û f ˎ i Ə ǵ õ ̮ ĝ Ő ; K 9 Ư { \ ʑ ʐ ɡ ĝēκBˌÒ˿͇uφÎŦ̢myonectin ŋͬ˗ erythroferroneKžǠ·ƅ͆^Ƀ§KY`ĝΡ~Ƌƍ

4572 ISSN 2095-4344 CN 21-1581/R CODEN: ZLKHAH Li L, Yu L. Biological role of myonectin and its correlation with exercise. Zhongguo Zuzhi Gongcheng Yanjiu. 2018;22(28):4568-4573. DOI:10.3969/j.issn.2095-4344.0266

Ɵͥͻġžuŷĕ),VÎŦĆƍƟȴ͇ΝDȋě̓R [12] Seldin MM,Lei X,Tan SY,et al.Skeletal muscle-derived myonectin ĝǒüKƯŒÎŦƋʘǠΌƏmyonectinĝÚ͠Ɨ͸ŀ activates the mammalian target of rapamycin (mTOR) pathway to suppress autophagy in liver.J Biol Chem.2013;288(50): 36073-36082. “˫ǫΖK9Æmyonectin˼ÎŦŭϏʩˊĝΡ~æÝ [13] Kautz L,Jung G,Valore EV,et al.Identification of erythroferrone as an ȴ͇ΝDĝƍƟƏɫʦŨǒɻĝŷĕVʲνKuʩ erythroid regulator of iron metabolism.Nat Genet.2014;46:678-684 myonectinĝΡ~0ºKΓÛʦ͸ɷˏ≠˴LJĕȁǮ= [14] Honda H,Kobayashi Y,Onuma S,et al.Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, DŨÛŨ),ġ͆±øƷ˫˼ƸƔV and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis.PLOS ONE.2016;11:e151601. ň້ᯥDzවẴ᪂ᩥ3ᰈΚ▊3t&ৰPň້NJ˷ত᪈Ĝ&Ởᩳ [15] Kautz L, Jung G, Nemeth E,et al. Erythroferrone contributes to ň້zš4e recovery from anemia of inflammation.Blood. 2014,124:2569-2574. ඓ᯽Γť᪩তȉǛr8ęǪႮϢ࢕ƚȖₕ(31500964)◑ᆵνྲྀȖ [16] Nai A,Rubio A,Campanella A,et al.Limiting hepatic Bmp-Smad ₕĆ(151095)ęǪĿྲྀʇɴ͔ʥɑᵯ᫂L(2015B046)ě˜Ŀྲྀ̓ƚႮ'࢕ signaling by matriptase-2 is required for erythropoietin-mediated ᫂L(2016YB047 2017YB028)9Ոᰈ­4¤ƅň້̌Š ඓ᯽Γť̵ƅƽ hepcidin suppression in mice.Blood.2016;127:2327-2336ۘ ɜɰཐཐ༘௤۔Ȍǎ͢ĉ἗4e [17] Ŭ☗,ጧΑļ,Ƞ᫬,਍.ᲕǴẔ¬ȭʌ࿆Ģ“᪵ȰՈཀྵྚ̓ ˑতᢆͥʐȭۘऺϔǒǖᢆ඗ȘՈඣᩥ .֎ΞॅতՈ͔ᾬň້̌Š ń᫂Lۘऺʐত̔΅ẋ࣏ ̵ƅü͢ ᜬẂՈƽˑ[J].ęẔ¬Ŀƚƾȣ, 2016,35(6):547-552- ˋĹᢖᄶƽˑতᢆͥʐȭϔǒ඗ȘՈĉ἗ ]ƌń-֎Ξॅ4e [18] Peterson JM, Mart R, Bond CE.Effect of obesity and exercise on the Ēˊ⒲LতՈ̔΅^ේṕǚΝȒতἹƼr9ிඣවẴʐሣ዇ Ȍĉ expression of the novel myokines, Myonectin and Fibronectin type III Ɏᢈᇇ:(PRISMA ūś)4e domain containing 5.PeerJ.2014;2:e605. তɡₑতϦČQ>ඓẋ CNKI ǑेDz̼ϟிඣẟᜐ 3 Ƶɡₑ4 [19] Rodríguez A, Becerril S, Méndez-Giménez L, et al.Leptin ত̲ǕতඓęͱɃȐᜐ̲ǕcǪǐֶ̲Ǖ ৪ȌƨǕःNjd4e administration activates irisin-induced myogenesis via nitric ň້̌ŠৰPň້ȭۘऺʐ̔΅Ո᩾ϦɴՈ]঳ᜐ&ãĩᯧç4᩾ oxide-dependent mechanisms, but reduces its effect on subcutaneous 5ǎՈƣϧĚċ3ϔǒíĉŐᩥਜ਼ƶϔǒßóᩴơǎʳƨ>ŭ+ƅ͟ᢈǎlj fat browning in mice. Int J Obes (Lond). 2015;39(3):397-407. ƌ3 —ʐ⏄ɕ dzȉǛʴɡ4e [20] Yang M,Wei D,Mo C,et al.Saturated fatty acid palmitate-induced তČƿতϦČQƾȣ>^͔Ŀň້Ǭƿ¦ੂึrČƿּ͟œᩲ4e insulin resistance is accompanied with myotube loss and the impaired ᪊͝—᩼dzœᩲ:8ึ expression of health benefit myokine genes in C2C12 myotubes.LipidsکŌ΢ቻǚ̌Šẝ«PઋŌ΢ቻǚত ʵǒ9 . !9ǝǒ ńȌˊšϬՈ̑Ρ[ ̭᩼Â¦Ñ Health Dis.2013;12: 104 —ȑ☢͊ɳūϬּȐ5ś͝ ɳֲՈȖzƣͱǭේṕ3᫇ϘʐÍʉ Ȑr̭᩼çŁϬ›Ⓣᪿ3[ṁ3 [21] ┌«,NJÞ,Ŭᄷᄷ,਍.Ϝ͍᪵ȰՈɜɰཐǃĐǚ̩ẋ࣏ཐⒸ࿆Ʈɍƚǎ͊☢ śᯡ3ČỖ3·Ŵ3̼௦3᱉൫⏂ȉ᪩Dz Â&7ņএ௦š ϬňḳâՈṗ ཐ ͠üƄᜬẂǜĚ[J]. ęϣĭĚƚ^ Ƅϣĭƚĉ,2015,31(1): ͑ϔǒz͢ƷçŁȌͩϬỘ4
64-71. [22] Gamas L, Matafome P, Seiça R.Irisin and Myonectin Regulation in the 4 dž໇Dz References Insulin Resistant Muscle: Implications to Adipose Tissue: Muscle Crosstalk.J Diabetes Res.2015;8:121-128. [1] Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal [23] Chen T,Li ZW,Zhang YY,et al.Muscle-selective knockout of AMPK>2 muscle as a secretory organ. Nat Rev Endocrinol.2012;8(8): 457-465. does not exacerbate diet-induced obesity probably related to altered [2] Giudice J,Taylor JM.Muscle as a paracrine and endocrine organ.Curr myokines expression.Biochem Biophysic Res Com.2015;458(12): Opin Pharmacol.2017;34:49-55. 449-455. [3] Wong GW,Wang J,Hug C,et al. A family of Acrp30 / adiponectin [24] Sharma N,Castorena CM,Cartee GD. Greater insulin sensitivity in structural and functional paralogs[J]. Proc Natl Acad Sci USA.2004; calorie restricted rats occurswith unaltered circulating levels of several 101:10302-10307 important myokines and cytokines.Nutr Metab (Lond). 2012; 9(1):90. [4] Seldin MM,Peterson JM,Byerly MS,et al.Myonectin(CTRP15),a novel [25] Pedersen BK.The diseasome of physical inactivity — and the role of myokine that links skeletal muscle to systemic lipid homeostasis.J myokines in muscle-fat cross talk.J Physiol.2009;587:5559-5568. Biol Chem.2012;287(15):11968-11980. [26] Catoire M, Kersten S.The search for exercise factors in humans. [5] Noriyuki Ouchi and Kenneth Walsh.Cardiovascular and Metabolic FASEB J.2015;29(5):1615-28. Regulation by the Adiponectin/CTRP Family of Proteins.Circulation. [27] Hawley JA, Hargreaves M, Joyner MJ et al.Integrative biology of 2012;5(31):1524-1539 exercise. Cell.2014; 159(4):738-749. [6] Matsuzawa Y,Funahashi T,Kihara S,Shimomura I.Adiponectin and [28] Park SY,Choi JH,Ryu HS,et al.C1q tumor necrosis factor alpha-related metabolic syndrome.Arterioscler Thromb Vasc Biol.2004;24:29-33. protein isoform 5 is increased in mitochondrial DNA-depleted [7] Yi W,Sun Y,Lau WB,et al.C1q/TNF-related protein-3, a newly identified myocytes and activates AMP-activated protein kinase. J Biol Chem. adipokine, is a novel anti-apoptotic, pro-angiogenic,and 2009;284(41):27780-27789. cardioprotective molecule in the ischemic mouse heart. Circulation. [29] Lim S,Choi SH,Koo BK,et al.Effects of aerobic exercise training on 2012;125:134-145. C1q tumor necrosis factor alpha-related protein isoform 5 (myonectin): [8] Park SY, Choi JH, Ryu HS,et al. C1q tumor necrosis factor association with insulin resistance and mito-chondrial DNA density in alpha-related protein isoform 5 is increased in mitochondrial women.J Clin Endocrinol Metab.2009;97:88-93. DNA-depleted myocytes and activates AMP-activated protein kinase. J [30] Phielix E,Meex R,Moonen-Kornips E,et al.Exercise training increases Biol Chem.2009;284:27780-27789. mitochondrial content and exvivo mitochondrial function similarly in [9] Seldin M M,Wong G W.Regulation of tissue crosstalk by skeletal patients with type 2 diabetes and in control individuals.Diabetologia. muscle-derived myonectin and other myokines.Adipocyte.2012;1(4) : 2010;53(8):1714-1721. 200-202 [31] Xu FX,Zhou X,Shen F,et al.Decreased peripheral blood mitochondrial [10] Febbraio M, Abumrad NA, Hajjar DP, et al. A null mutation in murine DNA content is related to HbA1c, fasting plasmaglucose level and age CD36 reveals an important role in fatty acid and lipoprotein of onset in type 2 diabetes mellitus.Diabet Med.2012;29(7):e47-54. metabolism.J Biol Chem.1999;274 (27):19055-19062. [32] Jager S,Handschin C, St-Pierre J, et al.AMP-activated protein kinase [11] Ibrahimi A , Bonen A , Blinn WD, et al. Muscle -specific overexpression (AMPK) action in skeletal muscle via direct phosphorylalion of PGC-1 of FAT/CD36 enhances fatty acid oxidation by contracting alpha.Proc Natl Acad Sci U S A.2007; 104(29) :12017-12022. muscle ,reduces plasma triglycerides and fatty acids,and increases plasma glucose and insulin.J Biol Chem.1999;274(38):26761-26766.

P.O. Box 10002, Shenyang 110180 www.CRTER.org 4573